ATOS news

The company agreed to distribute contingent value rights (CVRs) to stockholders, tied to potential monetization of a future FDA priority review voucher for the (Z)-endoxifen product candidate. This non-cash dividend aims to maximize value for current investors while preserving corporate liquidity.

Atossa reported $26.1M in cash after dosing ~800 patients in two FDA priority review programs. It seeks a potential best-in-class oral therapy for estrogen-driven diseases.

Atossa Therapeutics reported second quarter 2026 financial results, highlighting clinical profile developments and rare pediatric disease designations, with updates on oncology science presented at ASCO and AACR conferences.

Atossa Therapeutics has issued common stock purchase warrants exercisable beginning December 12, 2026, with terms defined in a June 10, 2026 Securities Purchase Agreement. The warrants allow holders to purchase company common stock at specified exercise prices through termination dates based on warr…